Reversible and Irreversible Cardiac Dysfunction Associated with Trastuzumab in Breast Cancer

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.74, Iss.2, 2002-07, pp. : 131-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab-related cardiac events in the treatment of early breast cancer

By Fried Georgeta Regev Tslil Moskovitz Mor

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Mechanisms of Trastuzumab Resistance in Breast Cancer

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 3, 2009-03 ,pp. : 348-355

Bentham Science Publishers

Access to resources Recommend Favorite

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells

By Nahta Rita Esteva Francisco

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 2, 2004-02 ,pp. : 186-190

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

By Lin Nancy

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1057-1065

Springer Publishing Company

Access to resources Recommend Favorite

Ongoing trials with trastuzumab in metastatic breast cancer

By Bell R.

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 69-73

Springer Publishing Company

Access to resources Recommend Favorite